Checks heart rhythm continuously or intermittently during treatment
Part of Genetic & congenital, Heart & circulation clinical trials.
This study compares two ways of monitoring your heart rhythm while you start certain cancer treatments. It may help doctors detect heart rhythm changes earlier and decide which monitoring approach is better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are starting standard treatment: arsenic trioxide for acute promyelocytic leukemia, or capecitabine/ribociclib for a solid tumor
- You are at least 18 years old
- You do not have an allergy to adhesive patches (the sensors stick to your skin)
- You can understand the study and agree to sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses wearable heart monitors to check for heart problems during cancer treatment. Participants wear a small patch that tracks their heart rhythm, helping doctors detect issues early.
This study checks how often abnormal heart rhythms happen when you start a BTK inhibitor (used for certain blood cancers). It uses a small implanted heart monitor to record your rhythm continuously before and after starting the medication, so doctors can detect and manage problems early.
This study uses a small device placed under the skin to continuously monitor your heart rhythm while you take a BTK inhibitor (a type of targeted therapy for blood cancer). The goal is to catch irregular heartbeats early, which can be a side effect of these medicines.
This study looks at whether certain blood cancer treatments increase the risk of an irregular heartbeat called atrial fibrillation. It may help doctors understand which patients need closer heart monitoring.
This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.
This study helps people with newly diagnosed acute myeloid leukemia (AML) by closely monitoring their heart health during chemotherapy. It aims to detect any early heart problems caused by treatment so they can be managed sooner.
Hear when a new Long QT Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.